Forsta AP Fonden boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 429,300 shares of the biopharmaceutical company’s stock after buying an additional 14,600 shares during the period. Bristol-Myers Squibb makes up about 0.9% of Forsta AP Fonden’s portfolio, making the stock its 24th largest position. Forsta AP Fonden’s holdings in Bristol-Myers Squibb were worth $25,882,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Ellevest Inc. raised its holdings in shares of Bristol-Myers Squibb by 32.3% in the second quarter. Ellevest Inc. now owns 2,047 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 500 shares during the last quarter. Benedict Financial Advisors Inc. raised its holdings in shares of Bristol-Myers Squibb by 1.2% in the second quarter. Benedict Financial Advisors Inc. now owns 44,064 shares of the biopharmaceutical company’s stock valued at $2,591,000 after purchasing an additional 510 shares during the last quarter. WFA of San Diego LLC purchased a new stake in shares of Bristol-Myers Squibb in the second quarter valued at about $631,000. ARGI Investment Services LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the second quarter. ARGI Investment Services LLC now owns 25,688 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 190 shares during the last quarter. Finally, Kistler Tiffany Companies LLC raised its holdings in shares of Bristol-Myers Squibb by 22.4% in the second quarter. Kistler Tiffany Companies LLC now owns 17,830 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 3,268 shares during the last quarter. Hedge funds and other institutional investors own 72.61% of the company’s stock.

BMY traded down $0.63 on Friday, reaching $60.13. The company had a trading volume of 7,336,812 shares, compared to its average volume of 10,316,678. The business has a 50 day simple moving average of $84.33 and a 200 day simple moving average of $84.06. The company has a market cap of $136.06 billion, a price-to-earnings ratio of -601.24, a P/E/G ratio of 1.05 and a beta of 0.71. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.36 and a current ratio of 1.47. Bristol-Myers Squibb has a 52-week low of $45.76 and a 52-week high of $68.34.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.48 by $0.15. The firm had revenue of $10.13 billion for the quarter, compared to the consensus estimate of $10.04 billion. Bristol-Myers Squibb had a negative net margin of 1.61% and a positive return on equity of 28.47%. The business’s revenue was up 61.5% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.25 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 2.99%. The ex-dividend date of this dividend is Thursday, October 1st. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 38.38%.

In other news, EVP Sandra Leung sold 141,420 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $63.24, for a total value of $8,943,400.80. Following the transaction, the executive vice president now owns 432,744 shares in the company, valued at $27,366,730.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Giovanni Caforio sold 39,840 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $62.70, for a total transaction of $2,497,968.00. Following the completion of the transaction, the chief executive officer now owns 445,584 shares in the company, valued at approximately $27,938,116.80. The disclosure for this sale can be found here. Insiders have sold 186,587 shares of company stock worth $11,782,297 over the last three months. Insiders own 0.14% of the company’s stock.

Several research firms recently weighed in on BMY. Cfra restated a “buy” rating and set a $70.00 price target on shares of Bristol-Myers Squibb in a research report on Sunday, July 26th. Berenberg Bank began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, September 29th. They set a “buy” rating and a $73.00 price target for the company. Raymond James restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 25th. Truist began coverage on shares of Bristol-Myers Squibb in a research report on Friday. They set a “hold” rating and a $65.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Bristol-Myers Squibb from $74.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average target price of $77.53.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.